Restricted accessOtherFirst published online 2004-11
Subnormal Immunity to Hemophilus influenzae type b (Hib) in Previously Vaccinated Human Immunodeficiency Virus-Infected Children 59 Months of Age or Older and Response to Booster Doses of the Conjugate Vaccine
Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol. 1933;24:273.
2.
Madhi SA, Petersen K, Khoosal M, et al.Reduced effectiveness of Hemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type I infection. Pediatr Infect Dis J. 2002;21(4):315-321.
3.
Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clin Infect Dis. 2000;31(1):170-176.
4.
Peters VB, Sood SK. Immunity to Hemophilus influenzae type b polysaccharide capsule in children with HIV infection immunized with a single dose of Hemophilus vaccine. J Pediatr. 1994;125:74-77.
5.
Kale KL, King JC, Farley JJ, et al.The immunogenicity of Hemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants. Pediatr Infect Dis J. 1995;14:350-354.
6.
Choudhury SA, Hodes DS, Peters VB. Antibody response to booster doses of hepatitis B vaccine in HIV-Infected Children. Pediatr Infect Dis J. 1995;14:65-67.
7.
Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-19.
8.
Choudhury SA, Mishreki NK, Khan AJ. Significant Waning of Antibodies to Tetanus Toxoid in HIV-infected Patients. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1997.
9.
Recommendations of the Immunization Practices Advisory Committee (ACIP). Hemophilus b conjugate vaccines for prevention of Hemophilus influenzae type b disease among infants and children two months of age and older. MMWR. 1991;40: No. RR-1.
